It is a multitarget tyrosine kinase inhibitor (inhibiting VEGFR2/3, PDGFR, etc.)and is currently used to treat adult and pediatric hepatocellular carcinoma, but the efficacy of sorafenib as a monotherapy in HB has not been confirmed. Here, KDR is linked to hemoglobin measurement.